
Annual report 2025
added 02-21-2026
Cognyte Software Ltd. EBITDA 2011-2026 | CGNT
Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.[1]
EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.
EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.
However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.
Annual EBITDA Cognyte Software Ltd.
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 8.53 M | -4.24 M | -85.3 M | 32.2 M | 40.8 M | 44.6 M | 39.7 M | - | 2.14 M | 1.34 M | -7.34 M | -6.75 M | -7.68 M | -9.28 M | -11.1 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 44.6 M | -85.3 M | 2.69 M |
References
- Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.
EBITDA of other stocks in the Medical devices industry
| Issuer | EBITDA | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Acutus Medical
AFIB
|
-11.5 M | - | -26.83 % | $ 2.62 M | ||
|
Alphatec Holdings
ATEC
|
-4.64 M | $ 13.73 | -2.21 % | $ 2.06 B | ||
|
Allied Healthcare Products
AHPI
|
-815 K | - | 3.58 % | $ 2.21 M | ||
|
GenMark Diagnostics, Inc.
GNMK
|
-3.98 M | - | - | $ 1.77 B | ||
|
Apollo Endosurgery
APEN
|
-30.2 M | - | - | $ 475 M | ||
|
Avinger
AVGR
|
-16.3 M | - | -20.74 % | $ 369 K | ||
|
Obalon Therapeutics, Inc.
OBLN
|
-9.8 M | - | -5.86 % | $ 30.6 M | ||
|
AxoGen
AXGN
|
-1.19 M | $ 31.12 | -0.34 % | $ 1.43 B | ||
|
Axonics Modulation Technologies
AXNX
|
-53.2 M | - | - | $ 3.31 B | ||
|
Aziyo Biologics
AZYO
|
-26.8 M | - | 1.37 % | $ 20.5 M | ||
|
Apyx Medical Corporation
APYX
|
-16.6 M | $ 3.44 | 0.58 % | $ 119 M | ||
|
Conformis
CFMS
|
-42.2 M | - | - | $ 16.4 M | ||
|
ClearPoint Neuro
CLPT
|
-18.8 M | $ 12.98 | -14.39 % | $ 351 M | ||
|
Bio-Rad Laboratories
BIO
|
421 M | $ 270.55 | 0.41 % | $ 7.63 B | ||
|
BIOLASE
BIOL
|
-15.1 M | - | -13.19 % | $ 166 K | ||
|
Bruker Corporation
BRKR
|
437 M | $ 39.83 | -0.15 % | $ 5.94 K | ||
|
BioSig Technologies
BSGM
|
-12.7 M | - | 37.08 % | $ 85.7 M | ||
|
Boston Scientific Corporation
BSX
|
4.98 B | $ 74.69 | 1.66 % | $ 111 B | ||
|
CryoLife, Inc.
CRY
|
23.2 M | - | -4.14 % | $ 702 M | ||
|
EDAP TMS S.A.
EDAP
|
-18 M | $ 4.5 | -1.96 % | $ 168 M | ||
|
Electromed
ELMD
|
10.7 M | $ 24.17 | 1.05 % | $ 204 M | ||
|
CONMED Corporation
CNMD
|
120 M | $ 46.25 | 0.61 % | $ 1.44 B | ||
|
Soliton, Inc.
SOLY
|
-14.1 M | - | -1.42 % | $ 435 M | ||
|
Cardiovascular Systems
CSII
|
-32.1 M | - | 0.15 % | $ 844 M | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
88.4 K | - | -1.98 % | $ 98.3 M | ||
|
Itamar Medical Ltd.
ITMR
|
-8.53 M | - | 0.03 % | $ 1.58 B | ||
|
Misonix, Inc.
MSON
|
-15.9 M | - | - | $ 462 M | ||
|
Neovasc
NVCN
|
-31.1 M | - | - | $ 111 M | ||
|
Cutera
CUTR
|
-148 M | - | -10.19 % | $ 1.99 M | ||
|
Delcath Systems
DCTH
|
-12.3 M | $ 9.28 | -9.16 % | $ 265 M | ||
|
Intersect ENT, Inc.
XENT
|
-64.8 M | - | - | $ 955 M | ||
|
Dynatronics Corporation
DYNT
|
-1.97 M | - | 14.99 % | $ 929 K | ||
|
Eargo
EAR
|
-106 M | - | - | $ 10.2 M | ||
|
InMode Ltd.
INMD
|
86.1 M | $ 13.91 | -0.39 % | $ 899 M | ||
|
Second Sight Medical Products
EYES
|
-24.3 M | - | -0.97 % | $ 54.4 M | ||
|
IRIDEX Corporation
IRIX
|
-8.91 M | $ 1.47 | -2.0 % | $ 23.7 M | ||
|
IRadimed Corporation
IRMD
|
22.8 M | $ 100.65 | 0.15 % | $ 1.28 B | ||
|
Establishment Labs Holdings
ESTA
|
-45.3 M | $ 75.32 | -3.79 % | $ 2.12 B | ||
|
GBS
GBS
|
-9.67 M | - | -0.57 % | $ 7.12 M | ||
|
FONAR Corporation
FONR
|
9.84 M | $ 18.54 | -0.22 % | $ 122 M | ||
|
LivaNova PLC
LIVN
|
228 M | $ 70.57 | 0.4 % | $ 3.85 B | ||
|
Globus Medical
GMED
|
757 M | $ 95.47 | -0.77 % | $ 12.9 B | ||
|
Medtronic PLC
MDT
|
8.82 B | $ 96.23 | -0.44 % | $ 124 B | ||
|
MiMedx Group
MDXG
|
78.8 M | $ 4.89 | -7.48 % | $ 723 M | ||
|
Pulmonx Corporation
LUNG
|
-56.6 M | $ 1.56 | -4.6 % | $ 61 M | ||
|
Helius Medical Technologies
HSDT
|
-12.4 M | $ 1.91 | -12.07 % | $ 1.16 M | ||
|
Invacare Corporation
IVC
|
-65 M | - | - | $ 24.7 M |